Updates From The Phase Iii Keynote-061 Trial

Updates from the Phase III KEYNOTE-061 trial

Dr. Yoon on Updated Results of the KEYNOTE-061 Study in Advanced Gastric/GEJ Cancer

Long term survival data from the Phase III Keynote-054 trial

Dr. Zalupski on Implications of the KEYNOTE-061 Trial in Gastric Cancer

KEYNOTE-061: association between gene expression signatures & outcomes

Arlene Siefker-Radtke, ESMO 2019 - KEYNOTE-866 Phase III trial in bladder cancer

Touch Medical Media

KEYNOTE-859: pembrolizumab plus chemotherapy in G/GEJ adenocarcinoma

Dr. Finn on the Rationale for the Phase III KEYNOTE-240 Trial in HCC

KEYNOTE-811: trastuzumab + chemotherapy with or without pembrolizumab for HER2+ G/GEJ cancer

RECOURSE Trial: Phase III trial: The Onset of Neutropenia as a Treatment Response Indicator

Phase III TAGS Trial

KEYNOTE-061: Tumor gene expression and clinical outcome analysis

Clinical Data From the Phase III PRIMA trial

Targeted Oncology

Dr. Mirza on the Phase III NOVA Trial in Ovarian Cancer

8 in 8: Update on Immunotherapy for Resectable Lung Cancer

ThoracicSurgeons

Does KEYNOTE 061 Provide Rationale for Using PD-L1 Inhibitors in First-Line Gastroesophageal Cancer?

Dr. Shah on the Rationale for the KEYNOTE-590 Trial in Esophageal Carcinoma

Global Phase 3 innovaTV301 Trial Results

HPR

3-year follow-up of CheckMate 649: nivolumab + chemotherapy in GC/GEJC/EAC

Final analysis of KEYNOTE-585: pembrolizumab and chemotherapy in G/GEJ cancer